Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients

Vox Sanguinis

Volumn 112, Issue 3, 2017, Pages 249-256

  Nussbaumer, W ^a   Amato, M ^a   Schennach, H ^a   Astl, M ^a   Chen, C Y ^b   Lin, J S ^b   Corash, L ^b   Benjamin, R J ^b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b CERUS CORPORATION   (United States)

Author keywords

amotosalen; INTERCEPT Blood System; massive transfusion; pathogen reduction; platelets

Indexed keywords

AMOTOSALEN; THROMBOCYTE CONCENTRATE; FUROCOUMARIN DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANEURYSM SURGERY; APHERESIS DEVICE; ARTICLE; CHILD; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HEART SURGERY; HEART TRANSPLANTATION; HOSPITAL MORTALITY; HUMAN; INJURY; LENGTH OF STAY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MASSIVE TRANSFUSION; MITRAL VALVE REPLACEMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; VASCULAR SURGERY; AUSTRIA; CARDIOVASCULAR DISEASES; DRUG EFFECTS; HOSPITAL; INFANT; KAPLAN MEIER METHOD; LIVER DISEASES; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; RADIATION RESPONSE; THROMBOCYTE; ULTRAVIOLET RADIATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AUSTRIA; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; FEMALE; FUROCOUMARINS; HOSPITAL MORTALITY; HOSPITALS; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PLATELET TRANSFUSION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; ULTRAVIOLET RAYS; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 85013170768     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12489     Document Type: Article

References (23)

1. Amato M, Schennach H, Astl M, et al.: Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre. Vox Sang 2016; doi:10.1111/vox.12456 [Epub ahead of print].
2. Lin L, Dikeman R, Molini B, et al.: Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004; 44:1496–1504
3. Lin L, Hanson CV, Alter HJ, et al.: Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005; 45:580–590
4. McCullough J, Vesole DH, Benjamin RJ, et al.: Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104:1534–1541
5. Lozano M, Knutson F, Tardivel R, et al.: A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011; 153:393–401
6. van Rhenen D, Gulliksson H, Cazenave JP, et al.: Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101:2426–2433
7. Osselaer JC, Cazenave JP, Lambermont M, et al.: An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94:315–323
8. Osselaer JC, Messe N, Hervig T, et al.: A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48:1061–1071
9. Osselaer JC, Doyen C, Defoin L, et al.: Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009; 49:1412–1422
10. Cazenave JP, Waller C, Kientz D, et al.: An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010; 50:1210–1219
11. Cazenave JP, Isola H, Waller C, et al.: Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011; 51:622–629
12. Knutson F, Osselaer J, Pierelli L, et al.: A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 2015; 109:343–352
13. Cinqualbre J, Kientz D, Remy E, et al.: Comparative effectiveness of plasma prepared with amotosalen-UVA pathogen inactivation and conventional plasma for support of liver transplantation. Transfusion 2015; 55:1710–1720
14. Corash L, Benjamin RJ: The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen-ultraviolet A pathogen reduction treatment model. Transfusion 2016; 56(Suppl 1):S29–S38
15. Hess JR, Pagano MB, Barbeau JD, et al.: Will pathogen reduction of blood components harm more people than it helps in developed countries? Transfusion 2016; 56:1236–1241
16. Holcomb JB, Tilley BC, Baraniuk S, et al.: Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015; 313:471–482
17. Kerkhoffs JL, van Putten WL, Novotny VM, et al.: Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150:209–217
18. Borgman MA, Spinella PC, Perkins JG, et al.: The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007; 63:805–813
19. Holcomb JB, Jenkins D, Rhee P, et al.: Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma 2007; 62:307–310
20. Holcomb JB, Spinella PC: Optimal use of blood in trauma patients. Biologicals 2010; 38:72–77
21. Holcomb JB, Zarzabal LA, Michalek JE, et al.: Increased platelet: RBC ratios are associated with improved survival after massive transfusion. J Trauma 2011; 71:S318–S328
22. Holcomb JB, Donathan DP, Cotton BA, et al.: Prehospital transfusion of plasma and red blood cells in trauma patients. Prehosp Emerg Care 2015; 19:1–9
23. Hess JR, Holcomb JB: Resuscitating PROPPRly. Transfusion 2015; 55:1362–1364